MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.
Virtual Conference Details:
Presentation: Available on Thursday, August 15, 2024, 7:00 am ET
Presenter: Frederic Guerard, PharmD, CEO Opthea
The webcast will be accessible both via the link: https://journey.ct.events/view/bc8c5e95-651e-4824-bee8-923a1a7479fa and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Web: www.opthea.com
Last Trade: | US$3.34 |
Daily Change: | 0.11 3.41 |
Daily Volume: | 15,669 |
Market Cap: | US$513.990M |
December 19, 2024 November 26, 2024 November 15, 2024 November 12, 2024 October 10, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB